Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation

Abstract

Objective

This study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for treating relapsed CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods

Clinical data of 43 patients with B-ALL who relapsed after allo-HSCT were retrospectively analyzed. Twenty-two patients were treated with CAR-T cells (CAR-T group), and 21 with chemotherapy plus DLI (chemo-DLI group). The complete remission (CR) and minimal residual disease (MRD)-negative CR rates, leukemia-free survival (LFS) rate, overall survival (OS) rate, and incidence of acute graft-versus-host disease (aGVHD), cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were compared between the two groups.

Results

The CR and MRD-negative CR rates in the CAR-T group (77.3% and 61.5%) were significantly higher than those in the chemo-DLI group (38.1% and 23.8%) (P=0.008 and P=0.003). The 1- and 2-year LFS rates in the CAR-T group were superior to those in the chemo-DLI group: 54.5% and 50.0% vs. 9.5% and 4.8% (P=0.0001 and P=0.00004). The 1- and 2-year OS rates in the CAR-T versus chemo-DLI group were 59.1% and 54.5% vs. 19% and 9.5% (P=0.011 and P=0.003). Six patients (28.6%) with grade 2–4 aGVHD were identified in the chemo-DLI group. Two patients (9.1%) in the CAR-T group developed grade 1–2 aGVHD. Nineteen patients (86.4%) developed CRS in the CAR-T group, comprising grade 1–2 CRS in 13 patients (59.1%) and grade 3 CRS in 6 patients (27.3%). Two patients (9.1%) developed grade 1–2 ICANS.

Conclusion

Donor-derived anti-CD19 CAR-T-cell therapy may be better, safer, and more effective than chemo-DLI for B-ALL patients who relapse after allo-HSCT.

Keywords

CD19-positive B-cell acute lymphoblastic leukemia / relapse / donor-derived CD19 chimeric antigen receptor T cells / chemo-donor lymphocyte infusion

References

[1] RoskoA, WangHL, de LimaM, et al.. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol, 2017, 92(1): 42-49

[2] ShimoniA. Relapse of acute leukemia after a second allogeneic stem-cell transplantation; Is there any hope for cure?. Bone Marrow Transplant, 2022, 57(3): 336-337

[3] CollinsRHJ, ShpilbergO, DrobyskiWR, et al.. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol, 1997, 15(2): 433-444

[4] GökbugetN, StanzeD, BeckJ, et al.. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 2012, 120(10): 2032-2041

[5] ZeidanAM, FordePM, SymonsH, et al.. HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant, 2014, 20(3): 314-318

[6] GhisoA, RaiolaAM, GualandiF, et al.. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant, 2015, 50(1): 56-61

[7] DavilaML, BrentjensRJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol, 2016, 14(10): 802-808

[8] KebriaeiP, SinghH, HulsMH, et al.. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest, 2016, 126(9): 3363-3376

[9] BrudnoJN, KochenderferJN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, 2016, 127(26): 3321-3330

[10] ParkJH, GeyerMB, BrentjensRJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood, 2016, 127(26): 3312-3320

[11] MaudeSL, FreyN, ShawPA, et al.. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014, 371(16): 1507-1517

[12] SinghN, PerazzelliJ, GruppSA, et al.. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med, 2016, 8(320): 320ra323

[13] ZhangC, WangXQ, ZhangRL, et al.. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia, 2021, 35(6): 1563-1570

[14] ZhangC, KongPY, LiS, et al.. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. J Immunother, 2018, 41(6): 306-311

[15] LeeDW, SantomassoBD, LockeFL, et al.. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant, 2019, 25(4): 625-638

[16] JagasiaMH, GreinixHT, AroraM, et al.. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant, 2015, 21(3): 389-401

[17] Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021). Zhonghua Xue Ye Xue Za Zhi (Chinese), 2021,42(4):265–275

[18] RoddieC, PeggsKS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther, 2011, 11(4): 473-487

[19] KolbHJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood, 2008, 112(12): 4371-4383

[20] CollinsRHJr., GoldsteinS, GiraltS, et al.. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant, 2000, 26(5): 511-516

[21] JacobyE, BieloraiB, AvigdorA, et al.. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol, 2018, 93(12): 1485-1492

[22] ParkJH, RivièreI, GonenM, et al.. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med, 2018, 378(5): 449-459

[23] ChenY, ChengY, SuoP, et al.. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol, 2017, 179(4): 598-605

[24] HuaJ, ZhangJ, ZhangX, et al.. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant, 2021, 56(5): 1056-1064

[25] GhoshA, SmithM, JamesSE, et al.. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med, 2017, 23(2): 242-249

[26] AnwerF, ShaukatAA, ZahidU, et al.. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy, 2017, 9(2): 123-130

[27] MaudeSL, LaetschTW, BuechnerJ, et al.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med, 2018, 378(5): 439-448

[28] BrudnoJN, KochenderferJN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev, 2019, 34: 45-55

[29] HayKA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol, 2018, 183(3): 364-374

[30] Al MalkiMM, AldossI, StillerT, et al.. Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma and Leuk, 2016, 16(9): 519-522

[31] HaenSP, GrohC, SchummM, et al.. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. Ann Hematol, 2017, 96(5): 817-827

[32] NaglerA, LabopinM, DholariaB, et al.. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol, 2019, 186(5): 767-776

[33] RuutuT, de WreedeLC, van BiezenA, et al.. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant, 2015, 50(12): 1542-1550

[34] SchneidawindC, HagmaierV, FaulC, et al.. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. Ann Hematol, 2018, 97(12): 2491-2500

[35] ChristopeitM, KussO, FinkeJ, et al.. Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol, 2013, 31(26): 3259-3271

[36] ShahNN, LeeDW, YatesB, et al.. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol, 2021, 39(15): 1650-1659

[37] FreyNV, ShawPA, HexnerEO, et al.. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol, 2020, 38(5): 415-422

[38] JiangH, LiC, YinP, et al.. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol, 2019, 94(10): 1113-1122